Article
KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Oct 2015
Zheng Song, Huang Ke-er, Pan Yue-long, Zhou Yao, Pan Song-dan, Li Xin, Jia Jing, Zheng Xiao-liang, Tao De-you
Abstract excerpt
BACKGROUND AND AIMS: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the digestive tract and characterized by expression of KIT protein. Imatinib is the frontline therapy for metastatic and unresectable GIST patients showing clinical responses in 80 % of cases. Despite the often long-lasting clinical benefit seen in most patients treated with imatinib, many will eventually suffer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.